{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:35Z","timestamp":1786119335192,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1097\/mjt.0b013e3181985130","type":"journal-article","created":{"date-parts":[[2009,11,14]],"date-time":"2009-11-14T03:18:26Z","timestamp":1258168706000},"page":"487-495","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women"],"prefix":"10.1097","volume":"16","author":[{"given":"Jules I","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnali","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy O","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210202","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.tips.2006.05.008","article-title":"The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.","volume":"27","author":"Offermanns","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"R2-7-20210202","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man.","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem"},{"key":"R3-7-20210202","doi-asserted-by":"crossref","first-page":"94114","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"R4-7-20210202","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1007\/s11883-000-0093-1","article-title":"Mechanism of action of niacin on lipoprotein metabolism.","volume":"2","author":"Kamanna","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"R5-7-20210202","first-page":"31433421","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R6-7-20210202","first-page":"360381","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"R7-7-20210202","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R8-7-20210202","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R9-7-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11883-000-0096-y","article-title":"Niacin dosing: relationship to benefits and adverse effects.","volume":"2","author":"Capuzzi","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"R10-7-20210202","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.","volume":"62","author":"Birjmohun","year":"2004","journal-title":"Neth J Med"},{"key":"R11-7-20210202","doi-asserted-by":"crossref","first-page":"29U","DOI":"10.1016\/S0002-9149(98)00732-2","article-title":"A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.","volume":"82","author":"Morgan","year":"1998","journal-title":"Am J Cardiol"},{"key":"R12-7-20210202","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903].","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol"},{"key":"R13-7-20210202","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"key":"R14-7-20210202","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"2nd. Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid.","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"key":"R15-7-20210202","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(81)92627-1","article-title":"Is cutaneous flushing prostaglandin mediated?","volume":"1","author":"Phillips","year":"1981","journal-title":"Lancet"},{"key":"R16-7-20210202","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/clpt.1985.170","article-title":"Prostaglandins and nicotinate-provoked increase in cutaneous blood flow.","volume":"38","author":"Wilkin","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"R17-7-20210202","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells.","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R18-7-20210202","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-7-20210202","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/sj.jid.5700586","article-title":"Langerhans cells release prostaglandin D2 in response to nicotinic acid.","volume":"126","author":"Maciejewski-Lenoir","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R20-7-20210202","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D-2 receptor subtype 1.","volume":"81","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R21-7-20210202","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1080\/00498250601175565","article-title":"The pharmacokinetics and disposition of MK-0524, a prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys.","volume":"37","author":"Chang","year":"2007","journal-title":"Xenobiotica"},{"key":"R22-7-20210202","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.bmcl.2007.03.058","article-title":"Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.","volume":"17","author":"Levesque","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"R23-7-20210202","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective prostaglandin D2 receptor antagonist [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524).","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"key":"R24-7-20210202","first-page":"318","article-title":"Effects of the DP1-receptor antagonist MK-0524 on nicotinic acid-induced flushing in lipid clinic patients.","volume":"114","author":"Paolini","year":"2006","journal-title":"Circulation"},{"key":"R25-7-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"R27-7-20210202","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2165\/00003088-199018060-00004","article-title":"Pharmacokinetic drug interactions with oral contraceptives.","volume":"18","author":"Back","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"R29-7-20210202","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clpt.2004.01.003","article-title":"The effect of isotretinoin on the pharmacokinetics and pharmacodynamics of ethinyl estradiol and norethindrone.","volume":"75","author":"Hendrix","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R30-7-20210202","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/15287397709529555","article-title":"Comparative metabolism of 17alpha-ethynyl steroids used in oral contraceptives.","volume":"3","author":"Ranney","year":"1977","journal-title":"J Toxicol Environ Health"},{"key":"R31-7-20210202","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/dmd.107.014696","article-title":"Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.","volume":"35","author":"Karanam","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R32-7-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/dmd.106.011551","article-title":"Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.","volume":"35","author":"Dean","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R33-7-20210202","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bmcl.2006.10.055","article-title":"In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.","volume":"17","author":"Nicoll-Griffith","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"R34-7-20210202","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2006.04.022","article-title":"Determination of a prostaglandin D2 antagonist and its acyl glucuronide metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometric detection-a lack of MS\/MS selectivity between a glucuronide conjugate and a phase I metabolite.","volume":"837","author":"Schwartz","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R35-7-20210202","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1528-1157.2003.55602.x","article-title":"Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects.","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia"},{"key":"R36-7-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0010-7824(80)90125-0","article-title":"The effect of rifampicin on the pharmacokinetics of ethinyl estradiol in women.","volume":"21","author":"Back","year":"1980","journal-title":"Contraception"},{"key":"R37-7-20210202","first-page":"218","article-title":"Evaluation of interaction between fluconazole and an oral contraceptive in healthy women.","volume":"98","author":"Hilbert","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R38-7-20210202","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/S0002-9378(99)70694-0","article-title":"Benefits and risks of oral contraceptives.","volume":"180","author":"Sherif","year":"1999","journal-title":"Am J Obstet Gynecol"},{"key":"R39-7-20210202","first-page":"19","article-title":"Oral contraceptives: mechanism of action, dosing, safety, and efficacy.","volume":"81","author":"Sondheimer","year":"2008","journal-title":"Cutis"},{"key":"R40-7-20210202","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1210\/jcem-53-1-58","article-title":"Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.","volume":"53","author":"Dunn","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-7-20210202","first-page":"171","article-title":"Induction of sex hormone binding globulin (SHBG) by a single dose of norethindrone acetate\/ethinyl estradiol (NA\/EE) [Abstract].","volume":"61","author":"Boyd","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"R42-7-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0010-7824(02)00436-5","article-title":"Effect of four different oral contraceptives on various sex hormones and serum-binding globulins.","volume":"67","author":"Wiegratz","year":"2003","journal-title":"Contraception"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-200911000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:03:18Z","timestamp":1786039398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-200911000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181985130","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}